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Given the demographic imperative, dementia remains one of the major public health concerns of the coming generation (1). Dementia's economic costs and impact on quality of life make it a vital concern for clinicians and policymakers. Dr Nathan Herrmann's review of cognitive pharmacotherapy presents a cautiously optimistic perspective for a condition that had previously been thought to be hopeless and amenable only to supportive measures. Consequently, it is significant that cognitive enhancers also show evidence of improved functional ability, behaviour, and overall quality of life, together with reduced caregiver burden. While initial data focused on the efficacy of cognitive enhancers in treating the mild-tomoderate stage of dementia (assessed as Mini-Mental State Examination [MMSE] scores of 10 to 26), recent evidence highlights their usefulness in more severe cases. Further, there is evidence that dementias other than Alzheimer's disease (that is, Lewy body dementia and vascular dementia) may also benefit from treatment with cholinesterase inhibitors. Frontotemporal dementia, which is not associated with a cholinergic deficit, is unfortunately not affected by these agents. With regard to practice guidelines, Dr Herrmann's approach is realistic. Although preliminary data support the practice of switching cognitive enhancers if the first drug is not well tolerated or is ineffective, he cautions that the desperation of caregivers will make them more than willing to undertake treatments that are not well established, and these "promising new agents" should not be oversold.
Lorentz and colleagues from the University of Washington address practical and scientific issues related to effective cognitive screening. It is important to identify dementia early for several reasons (2) . The first is to provide a coherent explanation to patients and families for the observed changes in cognition, behaviour, mood, and functioning that are associated with dementia. Second, a great deal of planning is essential for individuals and families, including the preparation of a power of attorney for personal care and property, a will for orderly distribution of assets, and a living will for end-of-life care. Further, the identification of dementia highlights increased risks for delirium and focuses on the need to assess driving ability. Finally, the recent availability of effective treatment with cognitive enhancers (as described by Dr Hermann) makes it even more important to treat dementia early. For all these reasons, effective cognitive screening as a first step in diagnosing dementia is an essential element in our clinical armamentarium.
It bears emphasizing that screening is not in any way a diagnostic test but simply a signal for further assessment and investigation for the possible diagnosis of dementia. For screening to be implemented by front-line clinicians, it needs to be quick, acceptable to patients, and easy to score and administer, while retaining reasonable psychometric properties. Lorentz and others document this very well in their review of the Mini-Cog, which is a combination of the clock test and a 3-word recall.
While multiple scoring systems have emerged in the literature for clock drawing, most are excessively cumbersome and complicated and have bewildered clinicians in recent years. A simple scoring approach described by Lorentz and others and also recommended by Borson and others (3) is the system used by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (4) . In terms of psychometric properties, this approach seems to be as valid as the more detailed scoring systems and, hence, should be considered much more desirable. Finally, readers can review the pros and cons of various other brief cognitive screens that use innovative methodologies.
Countering the traditional nihilism associated with old-age psychiatry, Flint and Gagnon's critical review of ECT in latelife depression highlights the potential for recovery, even in severe and refractory cases. These authors point out that the elderly are most likely to receive ECT because they are less tolerant of psychotropics and because psychotic depression is not an uncommon presentation in late life. Their paper reviews many of the technical issues relevant to ECT, including electrical dose, electrode placement, and frequency and number of treatments. Many issues are specific to old age, including the increase in seizure threshold with aging and its impact on the dose of electricity administered. Moreover, the dose of electricity affects both efficacy and side effects, and it is this balance that is a challenge in clinical practice. Flint and Gagnon note the complex bidirectional relation of cognition and ECT in old age. Depression itself can produce cognitive impairment, and there are many instances of ECT resulting in improved cognition after the initial side effects have subsided.
We are reminded that there are no absolute contraindications to ECT, only relative ones. From a practical point of view, Flint and Gagnon recommend a twice-weekly frequency and discuss the positive and negative aspects of high-dose unilateral, compared with bilateral, ECT. Because follow-up reveals that more than 50% of elderly patients relapse post-ECT, they raise the issue of continuation and maintenance ECT but highlight practical obstacles to implementing these treatments. The careful, evidence-based approach described by Flint and Gagnon regarding the use of ECT in the elderly should encourage clinicians.
The 3 papers in this In Review section represent a high level of research and clinical expertise. One can only hope that this level of academic scholarship and clinical awareness will continue for the next generation, in which care of the elderly will be an even greater challenge and priority for the health care system.
